News
Press Releases
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
● TRB-071, a CD30 agonist antibody designed to activate and expand tissue Tregs and block the CD30L-mediated inflammatory pathway, is progressing through IND-enabling studies ● TRB-051, which is partnered with Lilly, is expected to advance into Phase 2a...
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
Data from human atopic dermatitis (“AD”) skin identify altered tissue Treg programs and support TNFR2 as a regulator of immune homeostasis in tissue TRB-061, a novel TNFR2 agonist, induced selective Treg activity in vitro and pharmacodynamic expansion of...
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist
By selectively augmenting regulatory T cells (“Tregs”), TRB-061 is designed to restore immune balance and promote repair in skin and other barrier tissues Sixteen-week Phase 1b data anticipated in the first half of 2027 SOUTH SAN FRANCISCO, April 29, 2026 – TRex Bio,...
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis The single ascending dose...
TRexBio to Participate in Upcoming Investor Conferences in September
South San Francisco, Calif., September 3, 2025 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that members of its management team will participate in two...
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Safety, pharmacokinetic, and pharmacodynamic data from healthy volunteers anticipated in 1H 2026 Designed to activate and expand tissue regulatory T cells (Tregs) without stimulating effector or innate immune cells, TRB-061 offers a potential new approach to immune...
